Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herceptin in Locally Advanced HER2+ Breast Cancer
NCT00133796Phase 2Terminated
- Sponsor
- Mothaffar Rimawi
- Start
- Oct 2001
- Primary completion
- Sep 2005
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in breast cancer, sponsored by Mothaffar Rimawi. Primary endpoint: The effects of Herceptin and its efficacy in women with HER-2 overexpressing advanced breast cancer at 1 year. Started Oct 2001; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00133796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00133796.